Related Experiment Videos
New approaches to the therapy of autoimmune diseases: rheumatoid arthritis as a paradigm
L W Moreland1, L W Heck, W Sullivan
1Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham 35294-0012.
Abstract:
Several therapeutic agents currently are used to treat rheumatoid arthritis (RA). However, there is no compelling evidence that any of these agents substantially alters the long-term destructive course of RA. Advances in biotechnology have led to a better understanding of mechanisms that underlie autoimmune diseases such as RA. Although the etiology of RA remains unknown, there now is considerable insight regarding the immune and inflammatory pathways that ultimately lead to cartilage and bone destruction. Therapies with monoclonal antibodies directed against cell surface constituents, fusion toxins against cell activation markers, and cytokine inhibitors all have been shown to be safe and possibly efficacious in early open trials in RA. They now are being more rigorously tested in double-blind, placebo-controlled trials. Early experience with these biologic agents in humans, as well as data obtained from the use of these agents in animal models of autoimmune disease, are reviewed. In addition, experimental studies with "blocking peptides" and immunization with autoreactive T cell receptor peptides will be reviewed, and implications for therapy in RA will be discussed.
Insights
New biologic agents, including monoclonal antibodies and cytokine inhibitors, show promise for treating rheumatoid arthritis (RA) by targeting immune pathways. Rigorous trials are underway to evaluate their long-term efficacy in altering RA
Area of Science:
- Immunology
- Rheumatology
- Biotechnology
Background:
- Current rheumatoid arthritis (RA) treatments lack compelling evidence for altering the disease's long-term destructive course.
- Advances in biotechnology enhance understanding of autoimmune disease mechanisms, including RA's immune and inflammatory pathways.
- Cartilage and bone destruction in RA result from complex immune and inflammatory processes.
Purpose of the Study:
- To review emerging biologic therapies for rheumatoid arthritis (RA).
- To discuss the safety and potential efficacy of novel RA treatments.
- To explore future therapeutic implications based on current research.
Main Methods:
- Review of early open trials and ongoing double-blind, placebo-controlled trials of biologic agents in RA patients.
- Analysis of data from animal models of autoimmune disease treated with biologic agents.
- Examination of experimental studies involving blocking peptides and T cell receptor peptides.
Main Results:
- Biologic agents, such as monoclonal antibodies and cytokine inhibitors, demonstrate safety and possible efficacy in early RA trials.
- Data from animal models support the potential of these novel therapies.
- Experimental approaches like blocking peptides show promise for future RA treatment.
Conclusions:
- Biologic agents represent a promising new frontier in rheumatoid arthritis (RA) therapy.
- Further rigorous clinical trials are essential to confirm the long-term benefits of these agents.
- Targeting specific immune pathways offers a potential strategy to modify the destructive nature of RA.